CLINICAL_TRIALS
trial_result
· 2022-01-19
Clinical Trial Update: Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
Summary
Post-marketing surveillance study in Korean COPD patients evaluating Vahelva Respimat; completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED | Results posted: 2022-01-19